Join us in London for our Cell 2025 event 11–12 November - Oxford Global’s flagship meeting for the cell culture, bioprocessing, and advanced therapies community. Cell 2025 is more than just a conference – it is a vital hub for collaboration across every stage of the value chain from bench to bedside. 

In an industry where innovation is accelerating at unprecedented speed, the ability to connect stakeholders from discovery through to commercial delivery has never been more important. Cell 2025 will unite over 1,000 senior-level attendees from pharma, biotech, academia, investors, technology providers, and regulatory bodies - creating a high-impact environment for strategic partnerships, knowledge exchange, and innovation.

A Landmark Gathering for a Transforming Industry 

Cell 2025 is deliberately designed to reflect the entire ecosystem of cell & gene therapy development and delivery. By bringing together experts from cell culture (upstream & downstream) bioprocessing, therapeutic developers and manufacturing to supply chain, the event bridges the critical touchpoints needed to advance therapies from concept to patient.

With 12 content tracks spanning three core programmes – Cell Culture & Bioprocessing, Advanced Therapy Development, and Cell & Gene Therapy Manufacturing – the agenda covers the most pressing challenges and transformative opportunities in the industry. The event features keynote addresses from world-renowned leaders including Bobby Gaspar (Co-Founder and CEO of Orchard Therapeutics), Professor Dame Molly Stevens (John Black Professor of Bionanoscience, University of Oxford), and Christof von Kalle (Director, BIH & Charité Clinical Study Center BIH Chair for Clinical and Translational Sciences). A dedicated Start-Up and Innovation Track will also shine a spotlight on emerging biotech talent and disruptive platforms, underscoring the event’s role in supporting next-generation innovation.

Exploring the Entire Value Chain 

In the Cell Culture & Bioprocessing programme, delegates will explore strategies for building stable, scalable, and high-performing cell systems. Sessions will delve into cell engineering, next-generation bioprocessing, 3D culture technologies, automation and process optimisation to accelerate both upstream and downstream workflows. This focus reflects the industry’s ongoing push for reproducibility, efficiency, and commercial scalability.

The Advanced Therapy Development programme will provide insights into cutting-edge analytical techniques, robust clinical translation strategies, patient engagement trials, first in human case studies and the evolving regulatory frameworks that shape therapeutic pipelines. Attendees will have the opportunity to engage with pioneering researchers working at the forefront of gene and cell therapy research, tackling the complex scientific and logistical challenges that define the field.

In Cell & Gene Therapy Manufacturing, the emphasis will be on intelligent manufacturing solutions and integrated supply chains. Delegates will learn about the latest advances in AI-enhanced production platforms, automation tools, and scalable processes that enable efficient, compliant delivery of next-generation therapies. 

Technology Trends Driving the Agenda 

Cell 2025 will take a close look at the technologies and methodologies driving the next phase of growth in the industry. Artificial intelligence and machine learning are now integral to manufacturing, enabling smarter bioprocessing and predictive analytics that streamline development and improve yields.

Automation continues to reshape both manufacturing and analytics, offering scalable, reproducible solutions that meet the demands of an expanding therapeutic pipeline. In parallel, regulatory processes are adapting to keep pace with these innovations, enabling faster and more efficient routes to patient access without compromising safety.

Beyond manufacturing, emerging science is also set to take centre stage. Regenerative Medicine research is unlocking new treatment possibilities in oncology, while microRNA technologies are opening the door to precise gene regulation. The integration of these advancements into the broader development process underscores the value of Cell 2025 in connecting diverse expertise to translate breakthroughs into clinical reality. 

A Platform for Collaboration and Action

The Cell 2025 format is designed not just for listening but for active engagement. Across its programmes, the event will facilitate deep-dive discussions, case study exchanges, and solution-oriented debates, ensuring attendees leave with actionable insights. Important panel discussions include;

  • Cell & Gene Therapy Investment in a Challenging Economy – top investors and industry leaders will discuss where smart investments are being made in CGT.
  • Executing Cell & Gene Therapy Studies with Patient Engagement in Mind - applications of filing R&D, how this process works in different geographies, all with a focus on patent engagement.
  • Navigating Global Regulatory Challenges in CGT - explore the latest guidance, global frameworks, and strategies for accelerating approval and patient access. 

 

By connecting leaders from every stage of the value chain, the meeting creates a rare opportunity to align innovation in early discovery with the practicalities of manufacturing, regulatory compliance, and market delivery. Whether the goal is to refine a bioprocessing workflow, integrate AI tools, optimise cell line development, or streamline regulatory protocols, the conversations at Cell 2025 are set to drive tangible progress.

Shaping the Next Decade of Advanced Therapies 

As the cell & gene therapy industry matures, it is clear that the path forward depends on collaboration, innovation, and a shared vision for patient impact. The pace of progress – from streamlined cell line engineering to fully automated manufacturing systems – is opening doors to therapies that where unknown a decade ago. 

In this context, Cell 2025 is more than a knowledge-sharing forum; it is a strategic meeting ground for shaping the future of the industry. By uniting the scientists, technologists, policymakers, and entrepreneurs driving change, the event strengthens the collective capacity to deliver safe, effective, and accessible therapies worldwide. 

Register now to join us in London 

For professionals working in any part of the cell culture or advanced therapy value chain, Cell 2025 offers unmatched access to the people, ideas, and solutions that will define the industry’s future.

As the challenges of cost, scale, and regulatory complexity continue to shape the field, the ability to connect the dots across discovery, development, and delivery is essential. Cell 2025 stands as a focal point for this integration, making it a must-attend for anyone committed to advancing the next generation of cell and gene therapies.